Abeona Therapeutics (ABEO) entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $155 million upon the closing of the transaction. Abeona was awarded the PRV following the U.S. Food and Drug Administration approval of ZEVASKYN on April 28, 2025. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- ABEO Earnings this Week: How Will it Perform?
- Biotech Alert: Searches spiking for these stocks today
- Buy Rating for Abeona Therapeutics Driven by FDA Approval and Strong Market Potential of ZEVASKYN
- Abeona Therapeutics price target raised to $20 from $15 at H.C. Wainwright
- Abeona Therapeutics’ Promising Outlook: FDA Approval and Strategic Pricing of Zevaskyn Drive Buy Rating